{"pmid":32297805,"title":"Real-time RT-PCR in COVID-19 detection: issues affecting the results.","text":["Real-time RT-PCR in COVID-19 detection: issues affecting the results.","Expert Rev Mol Diagn","Tahamtan, Alireza","Ardebili, Abdollah","32297805"],"journal":"Expert Rev Mol Diagn","authors":["Tahamtan, Alireza","Ardebili, Abdollah"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297805","week":"202016|Apr 13 - Apr 19","doi":"10.1080/14737159.2020.1757437","keywords":["COVID-19 detection","Real-time RT-PCR","SARS-CoV-2","false negative","false positive"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266651254652928,"score":8.233237,"similar":[{"pmid":31992387,"pmcid":"PMC6988269","title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.","text":["Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.","BACKGROUND: The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. AIM: We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. METHODS: Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. RESULTS: The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive - Global (EVAg), a European Union infrastructure project. CONCLUSION: The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.","Euro Surveill","Corman, Victor M","Landt, Olfert","Kaiser, Marco","Molenkamp, Richard","Meijer, Adam","Chu, Daniel K W","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Schmidt, Marie Luisa","Mulders, Daphne G J C","Haagmans, Bart L","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","Goderski, Gabriel","Romette, Jean-Louis","Ellis, Joanna","Zambon, Maria","Peiris, Malik","Goossens, Herman","Reusken, Chantal","Koopmans, Marion P G","Drosten, Christian","31992387"],"abstract":["BACKGROUND: The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. AIM: We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. METHODS: Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. RESULTS: The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive - Global (EVAg), a European Union infrastructure project. CONCLUSION: The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks."],"journal":"Euro Surveill","authors":["Corman, Victor M","Landt, Olfert","Kaiser, Marco","Molenkamp, Richard","Meijer, Adam","Chu, Daniel K W","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Schmidt, Marie Luisa","Mulders, Daphne G J C","Haagmans, Bart L","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","Goderski, Gabriel","Romette, Jean-Louis","Ellis, Joanna","Zambon, Maria","Peiris, Malik","Goossens, Herman","Reusken, Chantal","Koopmans, Marion P G","Drosten, Christian"],"date":"2020-01-30T11:00:00Z","year":2020,"_id":"31992387","week":"20205|Jan 27 - Feb 02","doi":"10.2807/1560-7917.ES.2020.25.3.2000045","keywords":["*2019-nCoV","*RT-PCR","*Wuhan","*diagnostics","*laboratory","*novel coronavirus","*outbreak","*testing"],"link_comment_in":"32156329","source":"PubMed","locations":["European"],"topics":["Diagnosis"],"weight":1,"_version_":1663352134852149248,"score":111.58866},{"pmid":32294051,"title":"Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2.","text":["Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2.","Most reverse transcription PCR protocols for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) include 2-3 targets for detection. We developed a triplex, real-time reverse transcription PCR for SARS-CoV-2 that maintained clinical performance compared with singleplex assays. This protocol could streamline detection and decrease reagent use during current high SARS-CoV-2 testing demands.","Emerg Infect Dis","Waggoner, Jesse J","Stittleburg, Victoria","Pond, Renee","Saklawi, Youssef","Sahoo, Malaya K","Babiker, Ahmed","Hussaini, Laila","Kraft, Colleen S","Pinsky, Benjamin A","Anderson, Evan J","Rouphael, Nadine","32294051"],"abstract":["Most reverse transcription PCR protocols for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) include 2-3 targets for detection. We developed a triplex, real-time reverse transcription PCR for SARS-CoV-2 that maintained clinical performance compared with singleplex assays. This protocol could streamline detection and decrease reagent use during current high SARS-CoV-2 testing demands."],"journal":"Emerg Infect Dis","authors":["Waggoner, Jesse J","Stittleburg, Victoria","Pond, Renee","Saklawi, Youssef","Sahoo, Malaya K","Babiker, Ahmed","Hussaini, Laila","Kraft, Colleen S","Pinsky, Benjamin A","Anderson, Evan J","Rouphael, Nadine"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294051","week":"202016|Apr 13 - Apr 19","doi":"10.3201/eid2607.201285","keywords":["2019 novel coronavirus disease","COVID-19","SARS","SARS-CoV-2","coronavirus","coronavirus disease","molecular detection","rRT-PCR","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266295726571521,"score":97.21941},{"pmid":32105304,"pmcid":"PMC7047852","title":"Positive RT-PCR Test Results in Patients Recovered From COVID-19.","text":["Positive RT-PCR Test Results in Patients Recovered From COVID-19.","JAMA","Lan, Lan","Xu, Dan","Ye, Guangming","Xia, Chen","Wang, Shaokang","Li, Yirong","Xu, Haibo","32105304"],"journal":"JAMA","authors":["Lan, Lan","Xu, Dan","Ye, Guangming","Xia, Chen","Wang, Shaokang","Li, Yirong","Xu, Haibo"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105304","week":"20209|Feb 24 - Mar 01","doi":"10.1001/jama.2020.2783","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352134436913152,"score":86.16164},{"pmid":32283141,"title":"Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","text":["Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.","J Infect","Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong","32283141"],"abstract":["An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application."],"journal":"J Infect","authors":["Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283141","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.051","keywords":["Colloidal gold-based","Covid-19","Immunochromatographic strip","Real-time RT-PCR","SARS-CoV-2","Serology"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","China","ICG strip"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664182200751357952,"score":83.42598},{"pmid":32276333,"title":"Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","text":["Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.","Int J Mol Sci","Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung","32276333"],"abstract":["The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed."],"journal":"Int J Mol Sci","authors":["Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276333","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ijms21072574","keywords":["COVID-19","COVID-19-nsp2 assay","GolayMetaMiner","SARS-CoV-2","clinical evaluation","genome subtraction","nsp2","real-time RT-PCR","sensitivity","specificity"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663798882920824832,"score":80.5099}]}